6Anderson SD,Shah NK,Yim J,et al.Efficacy and safety of ticagrelor:a reversible P2Y12 receptor antagonist.Ann Pharmacother,2010,44:524-537.
7Antman EM,Hand M,Armstrong PW,et al.2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2008,51:210-247.
8Anderson JL,Adams CD,Antman EM,et al.ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians,the Society for Cardiovascular Angiography and Interventions,and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.J Am Coll Cardiol,2007,50:e1-e157.
9James S,Akerblom A,Cannon CP,et al.Comparison of ticagrelor,the first reversible oral P2Y(12) receptor antagonist,with clopidogrel in patients with acute coronary syndromes:Rationale,design,and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.Am Heart J,2009,157:599-605.
10Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361:1045-1057.